Actively Recruiting
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Led by Eastern Hepatobiliary Surgery Hospital · Updated on 2026-01-23
50
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. The aim of this study is to investigate the efficacy and safety of GP-HAIC combined with immunosuppressants in the treatment of initially unresectable ICC patients, as well as its role in conversion therapy. A prospective study was conducted on the data of locally advanced unresectable ICC patients receiving GC-HAIC combined with immunosuppressive therapy, evaluating the treatment efficacy and safety.
CONDITIONS
Official Title
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with advanced unresectable intrahepatic cholangiocarcinoma (ICC) by histology or imaging
- At least one measurable tumor lesion according to RECIST 1.1 criteria
- Eastern Cancer Collaboration Group (ECOG) physical fitness status score of 0 or 1
- Expected lifespan of 3 months or more
- Liver function classified as Child Pugh A or B
- Sufficient organ function and laboratory tests meeting protocol requirements
- Not currently receiving systemic treatment for ICC
You will not qualify if you...
- Previously received systemic treatment for ICC
- ECOG physical condition score of 2 or higher
- Liver function Child Pugh grading greater than 8
- Life expectancy less than 3 months
- Having other malignant tumors or a history of other malignant tumors
- Severe dysfunction in organs such as heart, brain, lungs, or kidneys
- Allergy or intolerance to the investigational drug or its components
- Other conditions deemed unsuitable for participation by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, China, 200438
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here